A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A new pill that ‘slows down Alzheimer's ' is being considered for use in the NHS. Developed by a small British firm in ...

Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The study also integrates drug databases ... Women With Ovarian Removal Have Unique Risk and Resilience Factors for Alzheimer Disease Dec. 5, 2024 — New research has found that women who have ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

It raises the prospect of it being the third successive drug in a new era of Alzheimer’s treatments to not be approved for NHS patients amid concerns that Nice’s cost assessments of the ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...